Previous close | 136.34 |
Open | 136.66 |
Bid | 136.77 x 800 |
Ask | 136.80 x 1100 |
Day's range | 135.26 - 137.46 |
52-week range | 119.59 - 145.58 |
Volume | |
Avg. volume | 1,030,177 |
Market cap | 15.262B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 18.49 |
EPS (TTM) | 7.43 |
Earnings date | 24 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | 3.00 (2.18%) |
Ex-dividend date | 05 Apr 2024 |
1y target est | 147.00 |
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.